Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma

NCT ID: NCT01889797

Last Updated: 2017-05-05

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 32 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-12-31
• Study Completion Date: 2016-08-31

Brief Summary

Patients with previously untreated low tumor burden indolent Non-Hodgkin's Lymphoma (NHL) will receive either rituximab or GA101 weekly for 4 weeks followed by re-staging to determine response.

Rituximab, an anti-CD20 chimeric antibody, was approved by the United States Food and Drug Administration in 1998 for the treatment of patients with relapsed low-grade B-cell lymphomas. Clinically, four weekly doses of rituximab have proven to be well tolerated and effective in previously untreated as well as relapsed patients with low-grade lymphoma.

GA101 is an anti-CD20 humanized and glyco-engineered monoclonal antibody. GA101 has been shown to have increased antibody-dependent cellular cytotoxicity (ADCC) and direct cell-death induction compared to Rituximab. It is possible that GA101 may have greater efficacy than rituximab.

PrE0401 Sub-Study Evaluation of Corrected QT (QTc) Interval and Pharmacokinetic Parameters in Patients Participating in GA101 (Obinutuzumab)

Approximately twenty-five patients randomized to GA101 may participate in the sub-study. Electrocardiograms and blood samples will be obtained.

Detailed Description

According to the American Cancer Society, it is estimated that approximately 70,800 individuals will be diagnosed with non-Hodgkin's lymphoma (NHL) and over 18,990 men and women will die of the disease in 2014. The survival rates for patients with indolent NHL remained unchanged from the 1950s through the early 1990s, but recent evidence suggests that outcomes are improving. Indolent NHL is a particular challenge because it is an incurable disease requiring multiple treatments; yet relatively long survivals elevate the importance of quality of life associated with treatment.

Agents such as rituximab are active in patients with a low burden of disease and result in high response rates and durable remissions for most patients. However, the optimal therapeutic approach to patients with low-grade lymphoma with a low disease burden is controversial as conventional chemotherapy also results in high rates of response. Regardless of whether patients receive immunotherapy, chemotherapy, or a combination thereof, they unfortunately exhibit a continuing pattern of disease relapse and the median survival for newly diagnosed patients is between 7-10 years.

Rituximab and GA101 both target the CD20 antigen. The CD20 antigen is located on the surface of normal and malignant B-cell lymphocytes. An attractive feature of this target is that CD20 is not on hematopoietic stem cells, nor is it expressed in any great extent on other normal body tissues.

Studies in vitro have shown that rituximab predominantly induces antibody dependent cellular cytotoxicity (ADCC), but also binds complement and directly induces apoptosis in lymphoma cells.

GA101 shows increased ADCC related to an improved binding of the GA101 to the different allotypes expressed by natural killer cells and monocytes. It also has increased direct cell-death related to an elbow hinge amino acid exchange and Type II binding of the CD20 epitope. The safety of GA101 in NHL so far appears to be similar to that observed with rituximab in patients with NHL, except for a higher incidence of infusion-related reactions.

Depletion of malignant B-cells using anti-CD20 monoclonal antibodies has an acceptable safety profile, particularly in patients with low-grade B-cell lymphomas with a low disease burden. To determine whether treatment with GA101 results in better outcomes than that seen with rituximab and to determine which anti-CD20 antibody to utilize in future studies, we will conduct a randomized Phase II trial of rituximab and GA101 in patients with previously untreated low-grade lymphoma. Patients will receive either rituximab or GA101 weekly for 4 weeks followed by re-staging. The endpoints of the study will be the Complete Response (CR), Overall Response Rate (ORR), time to next treatment, progression free survival (PFS), and safety of each treatment arm.

PrE0401 Sub-Study Evaluation of Corrected QT (QTc) Interval and Pharmacokinetic Parameters in Patients Participating in GA101 (Obinutuzumab)

Patients randomized to GA101 and who consent to the sub-study will have electrocardiograms obtained pre and post Week 1 and Week 4 to investigate the effect of GA101 on QTc interval. Pharmacokinetic blood samples will also be done to evaluate serum concentrations of GA101 at the same time-points.

Conditions

Indolent Non-Hodgkin's Lymphoma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Arm A: Rituximab

Rituximab 375 mg/m² IV weekly for 4 weeks.

Group Type: ACTIVE_COMPARATOR

Arm A: Rituximab

Intervention Type: BIOLOGICAL

Rituximab 375 mg/m² IV x 4 weekly doses.

Arm B: GA101

GA101 1,000 mg IV weekly for 4 weeks.

Group Type: EXPERIMENTAL

Arm B: GA101

Intervention Type: BIOLOGICAL

GA101 1,000 mg (flat dose) IV x 4 weekly doses.

Interventions

Arm A: Rituximab

Rituximab 375 mg/m² IV x 4 weekly doses.

Intervention Type: BIOLOGICAL

Arm B: GA101

GA101 1,000 mg (flat dose) IV x 4 weekly doses.

Intervention Type: BIOLOGICAL

Other Intervention Names

IDEC-C2B8; Chimeric anti-CD20 monoclonal antibody; Rituxan; NSC# 687451; Obinutuzumab; RO5072759; huMAB<CD20>

Eligibility Criteria

Inclusion Criteria

Registration: Patients having both diffuse and follicular architectural elements will be considered eligible if the histology is predominantly follicular (≥ 50% of the cross-sectional area), and there is no evidence of transformation to a large cell histology.

• Biopsy-proven diagnosis of Grade 1 or 2 follicular non-Hodgkin's lymphoma with no evidence of transformation to large cell histology.
• Meet criteria for Low Tumor Burden:

• No nodal or extra nodal mass ≥ 7 centimeter (cm)
• <3 nodal masses >3 cm in diameter
• No systemic symptoms or B symptoms
• No splenomegaly >16 cm by CT scan
• No risk of compression of a vital organ.
• No leukemic phase with >5000/mm³ circulating lymphocytes.
• No cytopenias defined as:

• Platelets <100,000/mm³
• Hemoglobin (Hgb) <10 g/dL
• Absolute Neutrophil Count (ANC) <1500/mm³
• Must have Stage III or Stage IV disease.
• Baseline measurements/evaluations obtained within 6 weeks of registration. Patient must have at least one objective measurable disease parameter.
• Age ≥ 18 years.
• Eastern Oncology Cooperative Group Performance Status 0-1.
• Must not have received investigational agents within 30 days of registration.
• Signed Institutional Review Board (IRB)-approved informed consent.
• Willing to provide blood samples for research purposes.
• Women must not be pregnant or breastfeeding.
• Women of childbearing potential and sexually active males must use an accepted and effective method of contraception.
• No prior chemotherapy, radiotherapy or immunotherapy for lymphoma.
• No prior treatment with cytotoxic drugs or rituximab for a previous cancer or another condition (e.g. rheumatoid arthritis) or prior use of an anti-CD20 antibody.
• No prior use of any monoclonal antibody within 3 months of randomization.
• No history of severe allergic/anaphylactic reactions to humanized/murine monoclonal antibodies or known sensitivity/allergy to murine products.
• No history of prior malignancy except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for at least 2 years and did not require treatment with cytotoxic drugs or rituximab.
• No major surgery within 4 weeks prior to randomization, other than for diagnosis.
• Must be Human Immunodeficiency Virus (HIV) negative.
• Have adequate organ function without growth factor and/or transfusion support within ≤ 2 weeks prior to registration:

• ANC ≥ 1500/mm³
• Hgb ≥ 10 g/dL
• Platelets ≥ 100,000/mm³
• Serum Creatinine ≤ 2x Upper Limit Normal (ULN)
• Total Bilirubin ≤ 2x ULN
• AST (aspartate aminotransferase)/ALT (alanine aminotransferase) ≤ 5x ULN
• PTT (Partial Thromboplastin Time) or aPTT (activated Partial Thromboplastin Time) >1.5x the ULN in the absence of a lupus anticoagulant
• INR (International Normalized Ratio) >1.5x the ULN in the absence of therapeutic anticoagulation
• No active, uncontrolled infections (afebrile for ≥ 48 hours off antibiotics).
• Must not receive immunization with attenuated live vaccines within 28 days prior to registration or during the study period.
• Must be tested for hepatitis B surface antigen (HBsAg) and total hepatitis B core antibody (anti-HBc) within 2 weeks of registration. Patients who are chronic carriers of HBsAg and anti-HBc are excluded.
• Must be tested for hepatitis C antibody within 2 week of registration. If this test is positive, patients are excluded unless a hepatitis C virus ribonucleic acid (HCV RNA) is negative.
• No evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results, including significant cardiovascular disease (i.e., severe arrhythmia, myocardial infarction within the previous 6 months, unstable arrhythmias, or unstable angina) or pulmonary disease.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Genentech, Inc.

INDUSTRY

Sponsor Role: collaborator

PrECOG, LLC.

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Stephen Ansell, MD

Role: STUDY_CHAIR

Mayo Clinic in Minnesota

Locations

University of South Alabama

Mobile, Alabama, United States

Marin Cancer Care

Greenbrae, California, United States

St. Joseph's/Candler Health System

Savannah, Georgia, United States

Decatur Memorial Hospital

Decatur, Illinois, United States

Carle Cancer Center

Urbana, Illinois, United States

Indiana University

Indianapolis, Indiana, United States

Siouxland Hematology Oncology Associates

Sioux City, Iowa, United States

Ochsner Cancer Institute

New Orleans, Louisiana, United States

Greater Baltimore Medical Center

Baltimore, Maryland, United States

Tufts Medical Center

Boston, Massachusetts, United States

St. Joseph Mercy Health System

Ann Arbor, Michigan, United States

Mayo Clinic

Rochester, Minnesota, United States

Metro MN CCOP

Saint Louis Park, Minnesota, United States

Missouri Valley Cancer Consortium

Omaha, Nebraska, United States

Montefiore Medical Center

The Bronx, New York, United States

Aultman Hospital

Canton, Ohio, United States

University Hospitals Case Medical Center

Cleveland, Ohio, United States

Toledo Community Oncology Program

Toledo, Ohio, United States

Geisinger Medical Center

Danville, Pennsylvania, United States

Fox Chase Cancer Center

Philadelphia, Pennsylvania, United States

Reading Hospital

West Reading, Pennsylvania, United States

Susquehanna Health Cancer Center

Williamsport, Pennsylvania, United States

University of Virginia

Charlottesburg, Virginia, United States

Charleston Area Medical Center (CAMC)

Charleston, West Virginia, United States

Gundersen Health System

La Crosse, Wisconsin, United States

Dean Clinic

Madison, Wisconsin, United States

ProHealth Care, Inc.

Waukesha, Wisconsin, United States

Aurora Health Care

Wauwatosa, Wisconsin, United States

Countries

United States

References

Hainsworth JD, Litchy S, Burris HA 3rd, Scullin DC Jr, Corso SW, Yardley DA, Morrissey L, Greco FA. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. J Clin Oncol. 2002 Oct 15;20(20):4261-7. doi: 10.1200/JCO.2002.08.674.

Reference Type: BACKGROUND

PMID: 12377971 (View on PubMed)

Beers SA, Chan CH, French RR, Cragg MS, Glennie MJ. CD20 as a target for therapeutic type I and II monoclonal antibodies. Semin Hematol. 2010 Apr;47(2):107-14. doi: 10.1053/j.seminhematol.2010.01.001.

Reference Type: BACKGROUND

PMID: 20350657 (View on PubMed)

Mossner E, Brunker P, Moser S, Puntener U, Schmidt C, Herter S, Grau R, Gerdes C, Nopora A, van Puijenbroek E, Ferrara C, Sondermann P, Jager C, Strein P, Fertig G, Friess T, Schull C, Bauer S, Dal Porto J, Del Nagro C, Dabbagh K, Dyer MJ, Poppema S, Klein C, Umana P. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010 Jun 3;115(22):4393-402. doi: 10.1182/blood-2009-06-225979. Epub 2010 Mar 1.

Reference Type: BACKGROUND

PMID: 20194898 (View on PubMed)

Salles GA, et al. Efficacy and Safety of Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma: Results from a Phase I/II Study (BO20999) American Society of Hematology Annual meeting 2011 Abstract 268.

Reference Type: BACKGROUND

Sehn LH, Goy A, Offner FC, Martinelli G, Caballero MD, Gadeberg O, Baetz T, Zelenetz AD, Gaidano G, Fayad LE, Buckstein R, Friedberg JW, Crump M, Jaksic B, Zinzani PL, Padmanabhan Iyer S, Sahin D, Chai A, Fingerle-Rowson G, Press OW. Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study. J Clin Oncol. 2015 Oct 20;33(30):3467-74. doi: 10.1200/JCO.2014.59.2139. Epub 2015 Aug 17.

Reference Type: BACKGROUND

PMID: 26282650 (View on PubMed)

Other Identifiers

BO25454

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

PrE0401

Identifier Type: -

Identifier Source: org_study_id